Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Y. Sawara; M. Itabashi; C. Kojima; H. Tabata; D. Kamei; K. Kawanishi; T. Moriyama; H. Sugiura; M. Tsukada; T. Takei; T. Ogawa; T. Yoshida; J. Arai; K. Uchida; K. Tsuchiya; K. Nitta

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Y. Sawara, M. Itabashi, C. Kojima, H. Tabata, D. Kamei, K. Kawanishi, T. Moriyama, H. Sugiura, M. Tsukada, T. Takei, T. Ogawa, T. Yoshida, J. Arai, K. Uchida, K. Tsuchiya, K. Nitta

Pathology

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

Original language	English (US)
Pages (from-to)	69-72
Number of pages	4
Journal	Clinical Nephrology
Volume	72
Issue number	1
State	Published - Oct 26 2009

Keywords

Minimal change nephritic syndrome
Relapse
Remission
Rituximab

ASJC Scopus subject areas

Nephrology

Cite this

@article{d4bdead268ea4dd0885d65c17efb9fc0,

title = "Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome",

abstract = "Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.",

keywords = "Minimal change nephritic syndrome, Relapse, Remission, Rituximab",

author = "Y. Sawara and M. Itabashi and C. Kojima and H. Tabata and D. Kamei and K. Kawanishi and T. Moriyama and H. Sugiura and M. Tsukada and T. Takei and T. Ogawa and T. Yoshida and J. Arai and K. Uchida and K. Tsuchiya and K. Nitta",

year = "2009",

month = oct,

day = "26",

language = "English (US)",

volume = "72",

pages = "69--72",

journal = "Clinical Nephrology",

issn = "0301-0430",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "1",

}

TY - JOUR

T1 - Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

AU - Sawara, Y.

AU - Itabashi, M.

AU - Kojima, C.

AU - Tabata, H.

AU - Kamei, D.

AU - Kawanishi, K.

AU - Moriyama, T.

AU - Sugiura, H.

AU - Tsukada, M.

AU - Takei, T.

AU - Ogawa, T.

AU - Yoshida, T.

AU - Arai, J.

AU - Uchida, K.

AU - Tsuchiya, K.

AU - Nitta, K.

PY - 2009/10/26

Y1 - 2009/10/26

N2 - Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

AB - Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

KW - Minimal change nephritic syndrome

KW - Relapse

KW - Remission

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=70349239452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349239452&partnerID=8YFLogxK

M3 - Article

C2 - 19640390

AN - SCOPUS:70349239452

SN - 0301-0430

VL - 72

SP - 69

EP - 72

JO - Clinical Nephrology

JF - Clinical Nephrology

IS - 1

ER -

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this